Mesoblast Ltd (MESO) income statement
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30
$11.18−0.46 (-3.95%)
Close on Nov 19, 2026Market cap $1.45BP/E –Yield –
Mesoblast Ltd income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2026
- Gross margin
- 86.1%
- Operating margin
- –
- Net margin
- -47.8%
- Return on equity, FY2026
- –
Financial strength
- Current ratio
- 2.43
- Debt to equity
- –
- Debt to assets
- 16.8%
- Cash to current liabilities
- 126.9%
Valuation
- P/E ratio
- –
- Price to sales
- 12.06
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?